Coronavirus Resources & Readings

Sonal Chokshi and a16z editorial Posted March 8, 2020

Editor’s note: This is a list of selected resources on the novel coronavirus (formerly known as as 2019 n-CoV, now known as SARS-CoV-2) that causes COVID-19 disease. The list spans everything from official sources, trackers, and data sites to medical journal information hubs, background readings, and Twitter accounts. If you have suggestions for what to add here (please note, the list is not crowdsourced but carefully curated), please email sonal [at] a16z [dot] com. 

official sources 

CDC (Centers for Disease Control and Prevention, part of the U.S. Health and Human Services Department)

WHO (World Health Organization)

state/local resources (from the states with early community spread)

Want more a16z?

Sign up to get our best articles, latest podcasts, and news on our investments emailed to you.

Loading form...

Thanks for signing up.

See All NewslettersBy clicking the Subscribe button, you agree to the Privacy Policy.

trackers & data visualizations

Worldometer
[more on who they are]
https://www.worldometers.info/coronavirus/

Johns Hopkins CSSE
Center for Systems Science and Engineering at John Hopkins University
[see also: https://coronavirus.jhu.edu]
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6

phylogeny of the viruses around the world and over time
can filter by location, see sequences to see how closely related viruses are
https://nextstrain.org/ncov
https://www.gisaid.org/epiflu-applications/next-hcov-19-app/

map of reported cases from the New York Times
https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html

COVID-19 tracker by journalists from the Atlantic and others
collects information from all 50 U.S. states and D.C. to provide comprehensive public data on state-level testing
[more on who and on their methodology]
http://covidtracking.com/

COVID-19 test capacity tracking from AEI
from the American Enterprise Institute [about/funding sources]
https://twitter.com/COVID2019tests

doubling time from Our World in Data
[based on data from WHO, more about them]
https://ourworldindata.org/coronavirus

summary data at a glance
[data from official sources, dashboard built by highschooler]
https://ncov2019.live/data

cancelled events
[from editor at the Verge; see context at bottom (see also The Verge, The Atlantic on the topic)]
https://www.isitcanceledyet.com/

lists & data sites

cluster of related topics on knowledge engine Golden
includes lists/updates of potential treatments, vaccine development activity, screenings, & related materials [about]
https://golden.com/wiki/Cluster%3A_COVID-19-ZXJX9AR

nucleotide sequences, SRA sequences, reference genome
https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/

GenBank sequence data
search, retrieve, and analyze SARS-CoV-2 data [more about GenBank (from National Library of Medicine NCBI Virus)]
https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/virus?SeqType_s=Nucleotide&VirusLineage_ss=Wuhan%20seafood%20market%20pneumonia%20virus,%20taxid:2697049

list of clinical studies
[these are their search terms; includes appropriate synonyms]
https://clinicaltrials.gov/ct2/results?cond=%22wuhan+coronavirus%22

paper sites + medical journal hubs

LitCovid
curated, comprehensive hub for tracking up-to-date scientific information from the National Library of Medicine National Center for Biotechnology Information (provides access to research articles in PubMed)
[old link we had on this list of their search terms for PubMed/Medline is here]
https://www.ncbi.nlm.nih.gov/research/coronavirus/

articles in the Public Health Genomics and Precision Health Knowledge Base
selected by the Office of Public Health Genomics just to provide current awareness of the literature and news
https://phgkb.cdc.gov/PHGKB/phgHome.action?query=Coronavirus&action=search&Mysubmit=Search

NEJM
New England Journal of Medicine
https://www.nejm.org/coronavirus

JAMA
Journal of the American Medical Association
https://jamanetwork.com/journals/jama/pages/coronavirus-alert

Lancet
https://www.thelancet.com/coronavirus

Elsevier
(publisher of The Lancet among several other journals)
https://www.elsevier.com/connect/coronavirus-information-center

Nature
Nature Publishing Group
https://www.nature.com/subjects/sars-virus

recommended agency & media hubs

National Library of Medicine (from the National Institutes of Health)
coronavirus disease resources & information
https://www.nlm.nih.gov/index.html#Novel_Coronavirus

FDA 
updates from the U.S. Food & Drug Administration including approvals and authorizations
https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/coronavirus-disease-2019-covid-19

Stat News (from The Boston Globe)
free coverage outside paywall as well as weekday recap newsletters
[fund/support here]
https://www.statnews.com/tag/coronavirus/

system preparedness

on hospital preparedness
Eric Toner & Richard Waldhorn, John Hopkins Center for Health Security Clinicians’ Biosecurity News, February 27, 2020
“What U.S. hospitals should do now to prepare for a COVID-19 pandemic”

on country-based mitigation measures, defining factors, and unknowns with this epidemic
Roy Anderson, Hans Heesterbeek, Don Klinkenberg, T Déirdre Hollingsworth, Lancet, March 9, 2020
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30567-5/fulltext

on ‘flattening the curve’
Helen Branswell, Stat, March 11, 2020
https://www.statnews.com/2020/03/11/flattening-curve-coronavirus/
see also: The Economist, New York Times

annual report on global preparedness for health emergencies
Global Preparedness Monitoring Board, WHO, September 19, 2019
https://apps.who.int/gpmb/assets/annual_report/GPMB_annualreport_2019.pdf

community mitigation guidelines to prevent pandemics
CDC, et al, April 21, 2017
https://www.cdc.gov/mmwr/volumes/66/rr/rr6601a1.htm#_blank

company plans & remote working strategies

these are from companies sharing their own plans and strategies, culled here (without including our own recommendations or commentary on them):

proactive steps for employers to take
Cooley (law firm)
https://www.cooley.com/news/insight/2020/2020-03-06-proactive-steps-for-employers-to-take-in-coronavirus-covid19-outbreak

adapting the way we work when offices need to close
Slack on Slack
https://slackhq.com/managing-remote-work-in-slack

planning and response
Coinbase blog on Medium [from a Google doc first shared by CEO]
https://blog.coinbase.com/coinbase-planning-and-response-to-covid-2019-d0cb3379bc3e

sharing our remote first processes, tools, and guidelines
Super Evil Megacorp
https://www.superevilmegacorp.com/blog/2020/3/4/sharing-our-remote-first-processes-tools-and-guidelines-for-fellow-corona-dodgers

readings on global supply chain impact:

other background readings

on comparing coronavirus to the flu
Roxanne Khamsi, Wired, February 8, 2020
“the whataboutism of infectious disease is as dangerous as it is hackneyed”

on understanding R0, what it does and doesn’t tell us
Ed Yong, The Atlantic, January 28, 2020
“The deceptively simple number sparking coronavirus fears”

on understanding definitions of pandemics, etc.
Helen Branswell (with additional reporting by Andrew Joseph), STAT, February 12, 2020
“Understanding pandemics: What they mean, don’t mean, and what comes next with the coronavirus”

countering the misinfodemic

myth busters
advice for the public from the World Health Organization
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters

how to sift through misinformation during an infodemic
OneZero on Medium [see also: “sifting through the epidemic”]
https://onezero.medium.com/the-simplest-way-to-spot-coronavirus-misinformation-on-social-media-4b7995448071

fact checking memes & misinformation
https://www.snopes.com/collections/coronavirus-collection-memes/

fact checking government responses
investigates rumors about how governments and organizations around the world have responded to the crisis
https://www.snopes.com/collections/coronavirus-government-role/

Twitter accounts

high signal-to-noise accounts from those immersed in specific aspects (with links to backgrounds for more information about their credentials, affiliations/funding sources, etc.)

journalists

@helenbranswell – Helen Branswell

@kakape – Kai Kupferschmidt

@sciencecohen – Jon Cohen

agencies & institutions

@cdcdirector – Robert Redfield

@drnancym_cdc – Nancy Messonnier

@drtedros – Tedros Adhanom Ghebreyesus

@uwvirology – University of Washington Department of Virology

@jhsph_chs – Johns Hopkins Center for Health Security

@lshtm – London School of Hygiene & Tropical Medicine

topical experts (including lab affiliations/researchers)

@mlipsitch – Marc Lipsitch

@cmyeaton – Caitlin Rivers

@t_inglesby – Tom Inglesby

@trvb – Trevor Bedford

@k_g_andersen – Kristian Andersen

@florian_krammer – Florian Krammer

@p_openshaw – Peter Openshaw

@arimoin – Anne Rimoin

@michaelmina_lab – Michael Mina

@jennifernuzzo – Jennifer Nuzzo

@krutikakuppalli – Krutika Kuppalli

@angie_rasmussen – Angela Rasmussen

@rozeggo – Rosalind Eggo

other

@scottgottliebmd – Scott Gottlieb

@maiamajder – Maia Majumder

@ameshaa – Amesh Adalja

We’ve also been covering the novel coronavirus and COVID-19 disease on our news show, 16 Minutes, here

Thanks also to Jorge Conde, Nate Chang, Judy Savitskaya, Andy Tran, and Julie Yoo for their contributions to some of the above as well!

image: CDC

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
Bio + Health

Infinite Healthcare: What’s It Worth?

Jay Rughani, Jane Rhee, and Julie Yoo
General

The Lighthouse Playbook

David Booth
General

The Case for Scaling Venture

Erik Torenberg
General

Death of Software. Nah.

Steven Sinofsky

Expert News by a16z

We have built a network of experts who are deeply rooted in technology and how it’s shaping our future. Subscribe to our newsletters to receive their perspectives.

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.